Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 12/20 | 0.73 |
| ▸ | AURKA | O14965 | 10/20 | 0.73 |
| ▸ | PLK4 | O00444 | 3/20 | 0.73 |
| ▸ | AURKC | Q9UQB9 | 2/20 | 0.73 |
| ▸ | ABL1 | P00519 | 2/20 | 0.73 |
| ▸ | BCR | P11274 | 2/20 | 0.73 |
| ▸ | SRC | P12931 | 2/20 | 0.73 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.73 |
| ▸ | STK25 | O00506 | 1/20 | 0.73 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.73 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.73 |
| ▸ | GAK | O14976 | 1/20 | 0.73 |
| ▸ | MUSK | O15146 | 1/20 | 0.73 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.73 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.73 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.73 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.73 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.73 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.73 |
| ▸ | JAK2 | O60674 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL75631 | 0.90 | AURKB (0.76) | AURKBAURKAPLK4AURKCABL1 | |
| SCHEMBL75584 | 0.89 | AURKB (0.75) | AURKBAURKAPLK4AURKCABL1 | |
| SCHEMBL13004641 | 0.89 | AURKB (0.65) | AURKBAURKAPLK4AURKCABL1 | |
| SCHEMBL13199262 | 0.89 | AURKB (0.56) | AURKBAURKAPLK4AURKCABL1 | |
| SCHEMBL13004578 | 0.86 | AURKA (0.87) | AURKBAURKAPLK4AURKCABL1 | |
| Tozasertib SCHEMBL2682989 | 0.84 | AURKA (1.00) | AURKBAURKAPLK4AURKCABL1 | |
| SCHEMBL18651118 | 0.84 | AURKA (0.85) | AURKBAURKAPLK4AURKCABL1 | |
| SCHEMBL19826565 | 0.83 | AURKA (0.85) | AURKBAURKAPLK4AURKCABL1 | |
| SCHEMBL18656672 | 0.83 | AURKA (0.85) | AURKBAURKAPLK4AURKCABL1 | |
| SCHEMBL13004582 | 0.83 | AURKB (0.82) | AURKBAURKAPLK4AURKCABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1954277-B1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMA (US) | 2017-01-18 | — | — | EP | disclosed |
| EP-1954277-B1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMA (US) | 2017-01-18 | — | — | EP | disclosed |
| US-8637511-B2 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637511-B2 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637511-B2 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-28 | — | — | US | disclosed |
| US-20100310675-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100310675-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100310675-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-09 | — | — | US | disclosed |
| US-7767672-B2 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-03 | — | — | US | disclosed |
| US-7767672-B2 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-03 | — | — | US | disclosed |
| US-7767672-B2 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-03 | — | — | US | disclosed |
| US-20070259869-A1 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070259869-A1 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070259869-A1 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-08 | — | — | US | disclosed |
| WO-2007056221-A2 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100310675-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | ABL1, PRKDC, MAP3K5 | AURKB 131/4885AURKA 66/4885PLK4 244/4885 |
| US-20070259869-A1 | Aminopyrimidines useful as kinase inhibitors | ABL1, PRKDC, MAP3K5 | AURKB 131/4885AURKA 66/4885PLK4 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.